Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment

Table 3

Small molecule/biological therapeutics targeting the Notch pathway.

Molecule	Function	Phase/clinical trials	Cancer type	NCT Number
RO4929097	Gamma secretase inhibitor	Phase 2	Breast cancer, ovarian cancer, renal cell carcinoma	NCT01131234
LY900009	Gamma secretase inhibitor	Phase 1	Advanced solid tumor or lymphoma	NCT01158404
PF-03084014	Gamma secretase inhibitor	Phase 1/2	T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma	NCT00878189; NCT01981551
Enoticumab	Anti-DLL4 antibody	Phase 1	Advanced solid tumors and ovarian cancer	NCT00871559
Demcizumab	Anti-DLL4 antibody	Phase 1b/2	Advanced solid tumors, pancreatic cancer, ovarian cancer, and non-small cell lung cancer	NCT02722954; NCT01189968; NCT01189929
Tarextumab	Anti-Notch 2/3	Phase 1b/2	Solid tumors, Stage IV pancreatic cancer, and Stage IV small cell lung cancer	NCT01277146; NCT01647828; NCT01859741

The clinical trial information was accessed via https://clinicaltrials.gov with National Clinical TrialNumber (NCT Number).